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Abstract
Colorectal carcinoma occurs in 1 of 20 individuals in
most developed countries. The relapse after resection
with metastatic liver disease is a major cause of death.
7-t-Butyldimethylsilyl-10-hydroxycamptothecin (DB67)
has been incorporated into liposomes allowing for in-
travenous (i.v.) administration. A preclinical efficacy
study of liposomal DB67 was performed using the
colon carcinoma CT-26 cell line. The therapeutic dose
for DB67 and liposomal DB67 was found to be 7 mg/kg
per day using the qdx5/1 schedule. The results are
compared with those obtained with irinotecan. The
treatment with liposomal DB67 administered intrave-
nously was more effective in reducing the weight and
volume of primary spleen tumors and the weight and
extent of liver metastases than free DB67 or liposomal
DB67 administered intraperitoneally, but less effective
than irinotecan. When the primary tumor was resected,
treatment with liposomal DB67 administered intra-
venously was more effective in reducing the weight
and extent of liver metastases than DB67 or liposomal
DB67 administered intraperitoneally, and irinotecan.
DB67 showed a higher accumulation in spleen and
liver after its i.v. administration in liposomal form
compared with its free or liposomal form administered
intraperitoneally. DB67 and liposomal DB67 are more
effective than irinotecan in the treatment of liver
metastases after resection of the primary tumor.
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Introduction
Colorectal cancer occurs in 1 of 20 individuals in most
developed countries. Over 80% of colorectal carcinomas
are resectable at the time of diagnosis, but 50% of patients
subsequently relapse with metastatic disease caused by
the presence of micrometastases not detected at diagnosis
[1]. The liver is the most common site for metastases,
occurring in approximately 40% of cases. Surgery is the
standard therapy when liver metastases are resectable. How-
ever, in most cases, resection is not possible and chemother-
apy is the only therapy available. Therefore, designing better
systemic therapy for metastatic disease is a major challenge to
oncologists.
In phase II clinical trials in patients with metastatic colorectal
carcinoma, irinotecan (Pfizer, Inc., New York, NY) has dem-
onstrated activity in chemotherapy naı¨ve patients and patients
previously treated with 5-fluorouracil (5-FU) [2,3]. 5-FU has
been the only cytotoxic agent with significant activity in ad-
vanced colorectal cancer for more than 30 years. More re-
cently, compared with 5-FU and calcium folinate (leucovorin,
or LV) alone, the combination of irinotecan with 5-FU/LV has
demonstrated increased response rate, time to progression,
and survival as a first-line treatment in metastatic colorectal
cancer [4]. As a second-line treatment, after failure of 5-FU/
LV therapy, irinotecan prolongs survival of the patients com-
pared with classical supportive care or 5-FU by continuous
infusion [5,6].
Irinotecan and the other camptothecin derivatives belong to
the family of topoisomerase I (topo I) inhibitors. Topo I is a
nuclear enzyme with the function of relaxing supercoiled DNA.
Topo I inhibitors intercalate with DNA during replication, tran-
scription, recombination, and chromosomal decondensation.
Their mechanism of action depends on the formed DNA–topo I
intermediate, termed ‘‘cleavable complex.’’ They interfere with
the DNA breakage–reunion reaction catalyzed by the enzyme
stabilizing the new ternary complex (DNA–topo I inhibitor) [7].
As a result, DNA suffers single-strand breaks. If exposed for
a long time to topo I inhibitors, cellular DNA in replication is
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double-strand broken, leading the cell to apoptosis. Due to
this particular mechanism of action, topo I inhibitors are
specially cytotoxic to tumor cells because of their rapid
division.
Camptothecin, the first topo I inhibitor tested, had poor
solubility, which limited its administration. Its structure con-
tains an a-hydroxy-y-lactone pharmacophore, which exists in
two distinct forms at physiologic pH of 7.0 and above: one
is the ‘‘ring-closed’’ lactone form, which is fully inhibitory of
topo I, and the second is the ‘‘ring-open’’ carboxylate form,
which is inactive with respect to inhibition of topo I [8]. Human
serum albumin (HSA) preferentially binds to the carboxy-
late form of camptothecin with a higher affinity than the
lactone form; these interations result in camptothecin open-
ing more rapidly and completely in the presence of HSA than
in the absence of the protein [9]. This shifts the lactone/
carboxylate equilibrium toward the inactive carboxylate form,
limiting its bioavailability.
To overcome this major problem, two major rational
approaches were used [10]. The first one was the introduc-
tion of substituents in its chemical structure to interfere with
the bonding of the camptothecin carboxylate form to HSA.
Two examples are the compounds topotecan (Hycamtin;
SmithKline Beecham, Philadelphia, PA) (a 9,10-disubstitut-
ed camptothecin) and irinotecan (a 7,10-disubstituted camp-
tothecin), which do not bind with high affinity to HSA [11,12].
In addition to that, both have improved aqueous solubility
and better bioavailability than camptothecin [13]. Moreover,
irinotecan itself is synthesized as an inactive prodrug. To
become significantly active in vivo, it has to be metabolized
to form SN-38 by a carboxyesterase [14]. Unfortunately,
irinotecan has a complex metabolism and the large interpa-
tient variability in carboxyesterase activity directly affects its
activation to SN-38, which may compromise the toxicity and
efficacy of the drug [15–17]. The second approach was the
introduction of substituents in the analog’s chemical struc-
ture, promoting the partition of camptothecin into lipid
bilayers, thereby stabilizing the lactone form [18]. Lipophilic
camptothecins, like 9-amino-camptothecin, have shown a
higher intrinsic potency against topo I and an improved
in vivo antitumor activity in murine models [19,20]. It has
also been demonstrated that lipid bilayers, like liposomal
membranes, stabilize the lactone form of camptothecins
[21]. Continuing with this chemical development, 7-silyl-
camptothecins (silatecans) have shown significant in vitro
activity against tumor cell lines [22]. Among them, DB67
(NSC 708298) showed high activity, forming very stable topo
I cleavable complexes; a high lipophilicity; and an intrinsic
topo I– inhibitory activity [23]. Also, DB67 remained in the
lactone form at high levels in the presence of HSA [24] and
was readily incorporated in liposomal bilayers, maintaining
its active lactone form [25]. In addition, DB67 presented a
potent antitumoral activity against glioma [26].
In this study, we have performed a preclinical efficacy
study of liposomal DB67 using the murine colon carcinoma
CT-26 cell line. We have observed that the therapeutic
dose for DB67 and liposomal DB67 in tumor-bearing mice
was found to be 7 mg/kg per day using a schedule of daily
injection for 5 days/1 week (qdx5/1) both for intraperito-
neal (i.p.) and intravenous (i.v.) routes of administration.
Our results demonstrate that the incorporation of DB67 in
liposomes made possible the injection of the lipophilic drug
DB67 intravenously, thereby increasing liposomal DB67
therapeutic effectiveness, as compared with itself and its
free form administered intraperitoneally against liver metas-
tases of a murine colon carcinoma after resection of the
primary tumor. This enhanced efficacy is due to a higher
liver drug accumulation after using the i.v. route of injection.
Materials and Methods
Materials
1,2-Dimyristoyl-sn-glycero-3-phosphocholine (DMPC)
and 1,2-dimyristoyl-sn-glycero-3-phospho-sn-1-glycerol
(DMPG) ammonium salt were from Avanti Polar Lipids
(Alabaster, AL) and were used without further purification.
Irinotecan was Camptosar (irinotecan hydrochloride injec-
tion) from Yakult Honska Co. Ltd. (Tokyo, Japan). Triethyl-
amine and high-performance liquid chromatography
(HPLC)–grade acetonitrile were from Fisher Scientific (Fair
Lawn, NJ). Sucrose and chloroform were analytic grade from
Sigma Chemical Co. (St. Louis, MO). Polycarbonate mem-
branes with a pore size of 100 nm were obtained from
Whatman International Ltd. (Maidstone, England, UK). Lipo-
Fast-Pneumatic was from Avestin (Ottawa, Canada).
Synthesis of DB67
The synthesis of 7-t-butyldimethylsilyl-10-hydroxycamp-
tothecin (DB67) has been previously described [23]. DB67
was prepared from a 1 mg/ml stock solution dissolved in
dimethylsulfoxide (DMSO) (ACS, spectrophotometric grade;
Aldrich, Milwaukee, WI). For in vivo use, DB67 was diluted
with 70% DMSO and 30% sterile NaCl 0.9% solution (Abbott
Laboratories, North Chicago, IL) prior to use.
Liposome Preparation
For the preparation of liposomal DB67 (lipo-DB67), mix-
tures of DB67 in free form and phospholipids (DMPC:DMPG,
7:3 molar ratio) at a molar ratio of 1:30 were dissolved in
chloroform. The solvent was removed by rotary evaporation
at 40jC to 45jC, and the residual chloroform was removed
by keeping the flask in vacuum for 24 hours. The film was
hydrated with 10% sucrose. The suspension was extruded
10 times at 40jC to 45jC through a polycarbonate mem-
brane with a pore size of 100 nm, using Lipo Fast-Pneumatic.
The liposomal DB67 suspension was frozen in liquid nitrogen
and kept for 10 minutes, then transferred to a freeze-drying
chamber and freeze-dried. The binding of DB67 to liposomal
membranes was close to 100%. For in vivo use, lipo-DB67
was resuspended in sterile NaCl 0.9% solution to a final
concentration of 1.3 mg/ml. The resulting suspension was
shaken at 115 rpm at room temperature protected from light
for 1 hour. The average size of lipo-DB67 after suspension
was 185 ± 30 nm, measured by dynamic light scattering
with a submicron particle sizer (Model 370; Nicomp, Santa
Barbara, CA).
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In Vitro Studies
Cell culture The murine CT-26 colon carcinoma cell line
wasprovidedbyDr. I. J.Fidler (M.D.AndersonCancerCenter,
TX). This cell line was maintained in growth medium consist-
ingofDulbecco’smodifiedEagle’smedium/nutrientmixtureF-
12 ham (1:1) (SigmaChemical Co.), 5%heat-inactivated fetal
bovine serum (Biowhittaker, Walkersville, MD), 2% L-gluta-
mine (GibcoBRL,Grand Island,NY),and1%sodiumpyruvate
(Gibco BRL). Cultures were established in 75-cm2 flasks
(Costar, Corning, NY), maintained at 37jC in a humidified
atmosphere with 5% CO2 in air, and subcultured every 2 to 3
days with trypsin–versene mixture (Biowhittaker). In all
experiments, exponentially growing cultures and only single-
cell suspensions of viability greater than 90% (determined by
trypan blue dye exclusion) were used. Cells were examined
and found to be free ofMycoplasma (assayed byGene-Probe
Mycoplasma TC; Gene-Probe, Inc., Gaithersburg, MD) and
the following pathogenic murine viruses: Sendai virus, pneu-
monia virus, mouse hepatitis virus, minute virus, mouse
poliovirus, reovirus type 3, polyomavirus, mouse adenovirus,
lymphocytic choriomeningitis virus, ectromelia, lactate dehy-
drogenase virus, and epizootic diarrhea of infant mice
(assayed by Charles River Laboratories, Wilmington, MA).
Cytotoxicity assays Cytotoxicity was determined by the
MTT assay as described [27]. The initial cell plating density
was chosen to ensure a linear relationship between cell
number and absorbance at the end of the experiment.
Briefly, CT-26 cells growing in the culture flasks (Costar)
were trypsinized, and 100 ml of growth medium containing
2.5 103 cells was plated in each well of 96-well flat-
bottomed microtiter plates (Costar), 24 hours prior to the
assay. On the second day, 100 ml of growth medium,
containing serial dilutions of assayed drugs, was added to
each well. After 30 minutes or 2 hours (not for 48 hours) at
37jC, the cells were washed twice and incubated with
growth medium for a further 48 hours. In experiments
evaluating the effect of the continuous drug effect, cells
were incubated directly with drugs for 48 hours. At this point,
50 ml of 1 mg/ml 3-(4,5-dimethylazol-2-yl)2,5-diphenyltetra-
zolium (MTT) (Sigma Chemical Co.) dissolved in PBS was
added to each well and the cells were incubated for another
4 hours at 37jC. The medium was removed and the cells
were solubilized in 150 ml of DMSO (Aldrich). The number of
viable cells in each well was then determined by absorbance
at 540 nm measured on an automated ELISA microplate
reader model MRX (Dynex Technologies, Chantilly, VA).
Background absorbance of the medium was measured in
a triplicate set of control wells that contained the medium
and the MTT solution without cells, and was subtracted from
the absorbance measured in each of the sample wells. IC50
is defined as the concentration of drug that caused a 50%
inhibition of the control growth.
In Vivo Studies
Animals Female 6- to 8-week–old mice Hsd:ICR (CD-1)
were used for toxicity experiments (maximum tolerated
dose, or MTD) and Balb/C AnNHsd were used for therapy
experiments and tissue accumulation studies. Both were
obtained from Harlan (Indianapolis, IN). Mice maintained in
a specific pathogen-free environment were allowed to accli-
matize to their new environment for 1 week prior to the
beginning of experimental procedures. Experiments were
conducted under the auspices of the Institutional Animal
Care and Use Committee of the Albert Einstein College of
Medicine (AECOM) for humane treatment of animals.
Determination of MTD For the determination of the
MTD, drugs were suspended and given intraperitoneally
or intravenously using the (qdx5/1) schedule. For DB67
and liposomal DB67, the doses were 10 and 40 mg/kg per
day, whereas for irinotecan, the doses were 55 and 70 mg/
kg per day. Body weight (BW) in each group was moni-
tored twice weekly. Irinotecan at a concentration of 20 mg/ml
was further diluted in NaCl 0.9% and used within 1 hour
from preparation. The loss of 15% BW or greater is consi-
dered lethal and the MTD was determined. Changes in BW
were calculated by the formula: BW (%) = (AB)/B  100,
where A is the mean BW of mice at that day and B is the
mean BW of mice on day 0. Each treatment and control
group consisted of five mice.
Tumor models
Liver metastases. Mice were anesthesized with an i.p.
injection of Nembutal (pentobarbital) (Abbott Laboratories) at
a dose of 70 mg/kg. After shaving, a small incision was made
through the skin over the spleen. The spleen, visible through
the abdominal wall, was grasped with tissue forceps, and a
small incision was made over the tip. The 30-gauge needle
was inserted, at a shallow angle, into the spleen to a depth of
5 mm, and 5  104 viable CT-26 cells in 100 ml of serum-free
medium were injected at a slow rate. The syringe was slowly
removed, the spleen was released, and the incision in the
skin was closed with an autoclip. Seven days later, depend-
ing on the experimental design, mice were anesthesized and
the primary tumor was surgically resected.
Subcutaneous (s.c.) primary tumor. When the tumor was
induced subcutaneously, 5 104 viable CT-26 cells in 100 ml
of serum-free medium were injected in the left flank of Balb/C
mice at a slow rate with a 30-gauge needle. The growth of the
tumor was monitored every other day, and tumor volumes
were calculated from Vernier calipers using the following
formula: tumor volume = 0.5 lengthwidth2. When tumor
volume reached 0.1 cm3, drug treatment was initiated.
Animal weights were recorded twice weekly.
Therapy experiments Therapy started depending on
experimental design: 1) on day 10 after intrasplenic cell
inoculation; 2) 7 days after primary tumor resection; or 3)
when s.c. primary tumor reached a size of nearly 0.1 cm3.
Mice were randomly assigned to be injected intravenously or
intraperitoneally with the drugs using the (qdx5/1) schedule.
The dose was 7 mg/kg per day for DB67 or liposomal DB67,
and 55 mg/kg per day for irinotecan. All treatments were
given within less than 1 hour after drug solution preparation
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to avoid drug hydrolysis [28]. Each group of mice was
weighed three to five times weekly until the weight nadir
was reached. The groups were weighed once or twice
weekly until the end of the experiment. In the liver metasta-
ses model, when the increase in liver volume was visible and
mice were moribund (as determined by a blinded observer),
mice were sacrificed and their livers were weighed. For the
s.c. tumor model, the experiment was ended when mice
tumors reached a volume of 2.0 cm3. The incidence of s.c.
tumors and liver metastases was 100%. In this set of experi-
ments, the group size was 7 to 10 mice per group. In survival
experiments, mice were kept alive until moribund to deter-
mine survival time, and the increase in lifespan (ILS) was
determined (median survival treated mice/median tumor
control mice)  100100. Mice that survived to 21 days
without requiring sacrifice were retreated with up to three
additional 21-day cycles of therapy. We define a 21-day
cycle of therapy as a treatment that consists of a daily
injection of drug for 5 days following 16 days without treat-
ment. In this other set of experiments, the group size was six
to seven mice per group. In all cases, mice were necropsied
to determine tumor load when moribund.
Necropsy procedures and histologic studies Mice were
sacrificed by cervical dislocation after sedation with Nembu-
tal, and their primary tumors and/or livers were excised and
weighed. For hematoxylin and eosin staining procedures, a
section of the tumor tissue was formalin-fixed and paraffin-
embedded. Macroscopically visible liver metastases were
counted under a dissecting microscope.
Tissue accumulation of DB67 Healthy female Balb/C mice
were injected intraperitoneally with DB67, and intraperito-
neally and intravenously with liposomal DB67, in all cases at
a single dose of 7 mg/kg. Samples were collected 0.5 and
2 hours after injection. Prior to this, mice were anesthesized
by i.p. administration of Nembutal and blood was collected
by cardiac puncture, placed in microtainer tubes with heparin
lock flush solution (100 USP U/ml; Wyeth Laboratories Inc.,
Philadelphia, PA), and centrifuged at 1500g for 10 minutes
to isolate the serum. Internal organs, liver, and spleen were
carefully removed, washed, blotted to remove attached
blood, weighed, and stored at 70jC. Tissue accumulation
of DB67 was measured as previously described [29]. Briefly,
after the liver and spleen tissue samples were thawed,
phosphate-buffered saline (PBS) buffer, pH 7.4, was added
for tissue extraction. The amount of PBS buffer was nine
times the amount of tissue. Tissues were homogenized
using a Brinkmann Polytron model PT1035 tissue homoge-
nizer. After homogenization, samples were vortexed and a
volume of 100 ml was transferred into a new microcentrifuge
tube. Following this, 3 ml of 1 M NaOH was added and
vortexed for 5 seconds, and the mixture was incubated for
5 minutes. Then, 400 ml of cold methanol was added and
vortexed for 5 seconds. Finally, the samples were centri-
fuged for 1 minute at 8000g. A volume of 200 ml from the
supernatant was removed and added to the same volume of
PBS, pH 12.0. The mixture was gently shaken and injected
into the HPLC. The HPLC system consisted of a Waters
Alliance 2690 separation module with aWaters 474 scanning
fluorescence detector. Separations were carried out on a
Waters Symmetry C18 5-mm column. The mobile phase
consisted of a mixture of 41% acetonitrile and 59% of an
aqueous buffer containing triethylamine and acetate. The
buffer (pH 5.5) contained 2% triethylamine added to distilled
deionized water with pH adjustment made with concentrated
acetic acid. Triethylamine acts as the ion pairing reagent,
masks underivatized silanols, and also serves as the major
buffer component. At this pH (5.5), the mobile phase pro-
vides adequate retention time of the carboxylate species.
A fluorescence detector was used with a kex = 380 nm and
kem = 560 nm, with a gain of 100. The flow rates used were
1 ml/min. DB67 calibration curve from controlled tissues was
performed by pipetting 250 ml of blank homogenized tissue
suspension into the test tubes. In the following step, standard
concentrations of DB67 were added to each specimen to
obtain a range of concentrations from 50 to 10,000 ng/ml.
Subsequently, each blank sample was processed to analyze
DB67 as previously described for treated tissues. The con-
centration of DB67 (carboxylate form) was determined from
peak area ratios of the compound by reference to a calibra-
tion curve run daily. The results of DB67 tissue accumulation
are expressed as percentage of the injected dose ±SD per
gram of tissue of five mice per group.
Statistical analysis The statistical significance of the differ-
ences was determined by the paired Student’s t test. The
significance of the differences between treatments in the
survival experiments was determined using the log-rank test.
Results
Determination of MTDs for DB67 and Liposomal DB67:
Effect of Different Injection Routes
Camptothecins are S-phase–specific drugs. Optimal
topo I inhibition is obtained when the tumors are exposed
to the drug for continuous periods of time. The schedule of
administration selected for topo I inhibitors was daily injec-
tions during 5 days (qdx5/1), best mimicking the clinical
situation [30]. The MTD of DB67 for the daily i.p. injection
during 5 days was first determined in healthy Hsd:ICR mice
(Figure 1A). Doses used were 10 and 40 mg/kg per day. At
40 mg/kg per day, mice had lost 20.3 ± 1.6% of their BW
(mean ± SD) and the dose had to be reduced to 10mg/kg per
day. At this dose, the nadir of BW loss occurred on day 3 and
reached 13.4 ± 0.7%, followed by an increase in BW from
that day on to a complete recovery by day 10. The MTD of
liposomal DB67 was also determined. At 40 mg/kg per day,
mice had lost 19.1 ± 3.9% of their BW and the dose had to
be reduced to 10 mg/kg per day (Figure 1B). At this dose, the
nadir of BW loss occurred on day 5 and reached 16.2 ± 2.8%,
followed by an increase in BW from that day on to a complete
recovery by day 12. In view of the excessive weight loss
caused by DB67 in both of its forms, free and liposomal, at a
dose of 10 mg/kg per day, the dose was reduced to 7 mg/kg
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per day in subsequent therapy experiments with Balb/C
tumor-bearing mice. In this case, the maximum weight loss
did not exceed 10%, which showed that the dose was well-
tolerated and treatment-related diarrhea was not observed in
our experiments with mice. DB67, in both of its forms, caused
similar parameters of acute toxicity such as ruffed fur,
hunched posture, and lethargy.
The MTD of irinotecan for the daily i.p. injection during
5 days was determined using a starting dose of 70 mg/kg per
day. Two days after the last injection (day 7), mice had lost
20.9 ± 1.9% of their BW (data not shown); therefore, the
dose was reduced to 55 mg/kg per day. At this dose, the
maximum weight loss in all cases did not exceed more than
10%. Similar results were found in therapy experiments with
Balb/C bearing-tumor mice. The dose of 52.5 mg/kg per day
has been previously defined as the higher nontoxic dose [31].
Thereafter, we examined the effect of the injection route
on the toxicity of liposomal DB67. The MTD of liposomal
DB67 for the daily i.v. injection during 5 days was determined
using a starting dose of 10 mg/kg per day; by day 5, mice had
lost 15.1 ± 0.4% of their BW, followed by an increase in BW
from that day on to a complete recovery by day 11 (Figure 2).
In view of the excessive weight loss, in the subsequent
therapy experiments, the dose was reduced to 7 mg/kg per
day. In this case, the maximum weight loss in all cases did
not exceed 10%, which showed that the dose was well-
tolerated. For i.v. injection of irinotecan, the results obtained
were similar to those found with the i.p. injection route. At a
dose of 55 mg/kg per day, the maximum weight loss in all
cases did not exceed 10% and was the dose used in therapy
experiments with Balb/C tumor-bearing mice. No differences
in the acute toxicity of irinotecan using different injection
routes and a daily treatment schedule have been previously
described [32]. Treatments with DB67, liposomal DB67, and
irinotecan may be considered as equitoxic as required for
analyzing differences in therapy experiments. Signs of acute
toxicity such as ruffed fur, hunched posture, or lethargy were
evaluated. No toxic deaths occurred in any of the experi-
ments that followed.
Therapeutic Effect of DB67 and Liposomal DB67 on Primary
Tumor-Bearing Mice: Effect of Different Injection Routes
CT-26 is a murine colon carcinoma that metastasizes to
the liver when injected intrasplenically. However, after a suf-
ficient period of time, the spleen can be removed without
affecting the ability to grow tumor cells already in the liver.
Balb/C mice were given intrasplenic injections of 5 104
viable CT-26 cells on day 0. On day 10 after tumor cell
Figure 1. Toxicity of DB67 and liposomal DB67. Hsd:ICR mice were injected
intraperitoneally on a schedule of daily injection for 5 days (qdx5/1). (A)
DB67: 10 mg/kg (.), 40 mg/kg (n), control (not treated) (5). (B) Liposomal
DB67: 10 mg/kg (.), 40 mg/kg (n), or control (not treated) (5). The data are
represented as mean weights ±SD with five mice per group. Arrows indicate
the day of treatment.
Figure 2. Toxicity of liposomal DB67. Hsd:ICR mice were injected intra-
venously on a schedule of daily injection for 5 days (qdx5/1) with 10 mg/kg
liposomal DB67 (.) and control (not treated) (5). The data are represented
as mean weights ±SD with five mice per group. Arrows indicate the day
of treatment.
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inoculation, mice were given i.p. administrations of DB67
or liposomal DB67, both at a dose of 7 mg/kg per day,
and irinotecan at a dose of 55 mg/kg per day. Mice were
euthanized and necropsied when the control (vehicle) group
became moribund (on day 20 after tumor cell inoculation).
Necropsy confirmed that 100% of the control mice had
formed splenic primary tumor and metastasized to the
liver. The results of this set of experiments are shown in
Table 1. The treatments with DB67 and liposomal DB67 did
not produce a statistically significant reduction in the weight
or tumor volume of spleen tumors as compared with the
control (vehicle). On the contrary, irinotecan produced a sig-
nificant reduction in the weight and tumor volume of spleen
tumors as compared with the control (vehicle), DB67, and
liposomal DB67 (P < .0001, P < .01, and P < .01, respec-
tively). The weight and tumor volume of spleen tumors in
these mice were less than those of the control mice on the
day of the first injection.
On the other hand, the weight and extent of liver metas-
tases were statistically significantly reduced by the treatment
with DB67 and liposomal DB67 as compared with the control
(vehicle) (P < .005 and P < .002, respectively). Irinotecan, as
well, produced a significant reduction in the weight and
extent of liver metastases as compared with the control
(vehicle) and DB67 (P < .001 and P < .01, respectively). In
addition, irinotecan produced a significant reduction in the
weight and extent of liver metastasis (P < .01 and P < .03,
respectively) as compared with liposomal DB67. The weight
and extent of liver metastases in mice treated with irinotecan
did not significantly differ from those of the control mice on
the day of the first injection. It must be emphasized that,
although there is an apparent absence of effect of DB67 and
liposomal DB67 on weight and tumor volume of spleen
tumors, on the other hand, they have a significant effect on
weight and extent of liver metastases as compared with the
control (vehicle).
The next step was to examine the effect of the variation in
the injection route for the same experimental model. On day
10, mice were given i.v. administrations of liposomal DB67
or irinotecan. The results of this last set of experiments are
shown in Table 2. The treatment with liposomal DB67
produced a statistically significant reduction in the weight
and tumor volume of spleen tumors as compared with the
untreated controls (P < .002 and P < .025, respectively). The
treatment with irinotecan also produced a significant reduc-
tion in the weight and tumor volume of spleen tumors
as compared with the untreated controls (P < .0001 and P <
.002, respectively) and as compared with liposomal DB67
(P < .025). Again, the weight and tumor volume of spleen
tumors of these mice were less than those of the control mice
on the day of the first injection. In addition, the weight and
extent of liver metastases were significantly reduced by the
treatment with liposomal DB67 as compared with the un-
treated control (P < .025 and P < .002, respectively). Irino-
tecan produced a significant reduction in the weight and
extent of liver metastases as compared with the untreated
control (P < .001) and as compared with liposomal DB67
(P < .02 and P < .025, respectively). The weight and extent of
liver metastases in mice treated with irinotecan did not
significantly differ from those of the control mice on the day
of the first injection. The weight and volume of spleen tumors,
and the weight and extent of liver metastases in mice treated
with irinotecan did not differ significantly compared by the
route through which the treatment is given, either intraper-
itoneally or intravenously.
Therapeutic Effect of Liposomal DB67 on Splenectomized
Mice: Effect of Different Injection Routes
Following the previous experiments, Balb/C mice were
given intrasplenic injections of 5  104 viable CT-26 cells on
day 0. Seven days after tumor cell inoculation, mice were
splenectomized. On day 14, mice were given i.p. adminis-
trations of DB67 and liposomal DB67, both at a dose of
7 mg/kg per day, and irinotecan at a dose of 55 mg/kg
per day. Mice were euthanized and necropsied when the
control (vehicle) group became moribund (on day 21 after
tumor cell inoculation). The results of this set of experi-
ments are shown in Table 3. The treatments with DB67,
Table 1. Effect of Topo I Inhibitors on Spleen Tumors and Experimental Liver Metastases of Murine CT-26 Colon Carcinoma: Effect of Intraperitoneal
Injection Route.
Treatment Spleen Tumor Liver Metastasis
Incidence Spleen Weight (g) Mean Tumor Volume (cm3) Incidence Liver Weight (g) Median (range)
Control 8/8 2.31 ± 0.45 2.74 ± 0.58 8/8 4.54 ± 0.52 59 (50–70)
Control* 5/5 1.45 ± 0.24 1.50 ± 0.32 5/5 1.50 ± 0.32 11 (9–17)
DB67 7/7 2.06 ± 0.66 1.98 ± 0.71 7/7 2.57 ± 0.92y 33 (16–50)y
Lipo-DB67 7/7 1.97 ± 0.51 2.61 ± 1.03 7/7 2.53 ± 0.79z 27 (4–45)z
Irinotecan 8/8 0.86 ± 0.23§,b,# 0.49 ± 0.26§,b,# 8/8 1.45 ± 0.18§,b,# 10 (4–21)§,b,**
Balb/C mice were injected in the spleen with 5 104 viable CT-26 cells on day 0. On day 10 after cell inoculation, groups of mice were treated on a schedule of daily
injection for 5 days (qdx5/1) with i.p. injections of 7 mg/kg DB67, 7 mg/kg liposomal DB67, or 55 mg/kg irinotecan. Mice were sacrificed on day 20.
Median is the value of the variable that has an equal number of items on either side and divides a frequency distribution into two halves.
*On day 10 after cell injection.
yP < .005 as compared to control (vehicle).
zP < .002 as compared to control (vehicle).
§P < .0001 as compared to control (vehicle).
bP < .01 as compared to DB67.
#P < .01 as compared to liposomal DB67.
**P < .03 as compared to liposomal DB67.
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liposomal DB67, and irinotecan statistically significantly re-
duced the liver weight as compared with the control (vehicle)
(P < .005, P < .001, and P < .01, respectively). In addition, all
treatments significantly reduced the extent of liver metas-
tases as compared with the control (vehicle) (P < .001).
More importantly, the treatment with DB67 and liposomal
DB67 produced a significant reduction in the liver weight as
compared with irinotecan (P < .05).
Then, we examined the effect of the variation in the
injection route for the same experimental model. On day
14, mice were given i.v. administrations of liposomal DB67
or irinotecan. The results of this set of experiments are
shown in Table 4. The treatment with liposomal DB67 and
irinotecan significantly reduced the liver weight as compared
with the untreated controls (P < .005). In addition, both
treatments significantly reduced the extent of liver metasta-
ses as compared with the untreated controls (P < .001). More
importantly, the treatment with liposomal DB67 produced a
significant reduction in the liver weight and extent of liver
metastases as compared with irinotecan (P < .01 and
P < .001, respectively). The liver weight of mice treated with
liposomal DB67 did not significantly differ from those of the
control mice on the day of the first injection. The weight and
extent of liver metastases in mice treated with irinotecan did
not differ significantly by the route through which the treat-
ment is given, either intraperitoneally or intravenously.
Survival of Splenectomized Mice Treated with
Liposomal DB67
To further evaluate the antimetastatic effect of liposomal
DB67, survival of Balb/C mice bearing CT-26 liver metasta-
ses was determined. The treatment consisted of i.v. admin-
istrations starting 7 days after splenectomy, 14 days after cell
inoculation. The results of this set of experiments are shown
in Table 5. In experiment 1, the mean survival times ±SD
of the untreated control and liposomal DB67-treated group
at a dose of 7 mg/kg per day, and irinotecan-treated group at
a dose of 55 mg/kg per day were 21.0 ± 1.0, 30.5 ± 2.7, and
26.7 ± 3.6 days, respectively. Thus, the increase in the
lifespan was 45% for the liposomal DB67-treated group,
and 27% for the irinotecan-treated group, both compared
Table 2. Effect of Topo I Inhibitors on Spleen Tumors and Experimental Liver Metastases of Murine CT-26 Colon Carcinoma: Effect of Intravenous Injection Route.
Treatment Spleen Tumor Liver Metastasis
Incidence Spleen Weight (g) Mean Tumor Volume (cm3) Incidence Liver Weight (g) Median (range)
Control 7/7 2.33 ± 0.46 2.04 ± 0.65 7/7 3.87 ± 1.25 50 (43–70)
Control* 5/5 1.45 ± 0.24 1.50 ± 0.32 5/5 1.50 ± 0.32 11 (9–17)
Lipo-DB67 8/8 1.24 ± 0.36y 0.91 ± 0.45z 8/8 2.31 ± 0.59z 16 (3–27)§
Irinotecan 7/7 0.77 ± 0.24b,# 0.32 ± 0.19y,# 7/7 1.30 ± 0.13y,** 7 (2–17)#,§
Balb/C mice were injected in the spleen with 5 104 viable CT-26 cells on day 0. On day 10 after cell inoculation, groups of mice were treated on a schedule of daily
injection for 5 days (qdx5/1) with i.v. injections of 7 mg/kg liposomal DB67 or 55 mg/kg irinotecan. Mice were sacrificed on day 20.
Median is the value of the variable that has an equal number of items on either side and divides a frequency distribution into two halves.
*On day 10 after cell injection.
yP < .002 as compared to control (no treatment).
zP < .025 as compared to control (no treatment).
§P < .001 as compared to control (no treatment).
bP < .0001 as compared to control (no treatment).
#P < .025 as compared to liposomal DB67.
**P < .02 as compared to liposomal DB67.
Table 3. Effect of Topo I Inhibitors on Experimental Liver Metastases of
Murine CT-26 Colon Carcinoma When Injected i.p.
Treatment Liver Metastasis
Incidence Liver Weight (g) Median (range)
Control 9/9 5.00 ± 0.54 58 (45–80)
Control* 5/5 1.56 ± 0.49 9 (5–12)
DB67 9/9 2.55 ± 1.05y,z 25 (5–55)§
Lipo-DB67 9/9 2.52 ± 1.04y,z 16 (9–35)§
Irinotecan 9/9 3.45 ± 1.13b 35 (6–55)§
Balb/C mice were injected in the spleen with 5 104 viable CT-26 cells on
day 0. Seven days later, mice were splenectomized. On day 14 after cell
injection, groups of mice were treated on a schedule of daily infection for
5 days (qdx5/1) with i.p. injections of 7 mg/kg DB67, 7 mg/kg liposomal DB67,
or 55 mg/kg irinotecan. Mice were sacrificed on day 21.
Median is the value of the variable that has an equal number of items on
either side and divides a frequency distribution into two halves.
*On day 10 after cell injection.
yP < .005 as compared to control (vehicle).
zP < .05 as compared to irinotecan.
§P < .001 as compared to control (vehicle).
bP < .001 as compared to control (vehicle).
Table 4. Effect of Topo I Inhibitors on Experimental Liver Metastases of
Murine CT-26 Colon Carcinoma When Injected Intravenously.
Treatment Liver Metastasis
Incidence Liver Weight (g) Median, n (range)
Control 9/9 5.26 ± 0.54 55 (45–80)
Control* 5/5 1.56 ± 0.49 9 (5–12)
Lipo-DB67 10/10 1.85 ± 0.65y,z 7 (0–14)§,b
Irinotecan 10/10 3.51 ± 1.27y 34 (10–55)§
Balb/C mice were injected in the spleen with 5 104 viable CT-26 cells on
day 0. Seven days later, mice were splenectomized. On day 14 after cell
injection, groups of mice were treated on a schedule of daily injection for 5
days (qdx5/1) with i.v. injections of 7 mg/kg liposomal DB67 or 55 mg/kg
irinotecan. Mice were sacrificed on day 21.
Median is the value of the variable that has an equal number of items on
either side and divides a frequency distribution into two halves.
*On day 14 after cell injection.
yP < .005 as compared to control (no treatment).
zP < .01 as compared to irinotecan.
§P < .001 as compared to control.
bP < .001 as compared to irinotecan.
Liposomal DB67 Diminishes CT-26 Liver Metastases Lopez-Barcons et al. 463
Neoplasia . Vol. 6, No. 5, 2004
with the control (Table 5). In experiment 2, the mean sur-
vival times ±SD of the untreated control, liposomal DB67-
treated group, and irinotecan-treated group were 19.0, 30.8
± 3.9, and 26.5 ± 3.9 days, respectively. Thus, the increase
in the lifespan was 62% for the liposomal DB67-treated
group, and 39% for the irinotecan-treated group, both com-
pared with the untreated control (Table 5). In both experi-
ments, comparing to the untreated control, the treatment
with liposomal DB67 and irinotecan statistically significantly
extended the survival of mice with CT-26 liver metastases
(P < .01 and P < .05, respectively). Furthermore, in each
experiment, one long-term survivor for more than 90 days
was found after three 21-day cycle treatments with liposo-
mal DB67. The results clearly show that liposomal DB67 is
more effective than irinotecan in prolonging the life of liver
metastases–bearing mice.
Tissue Accumulation of DB67 After Its Administration in
Free or Liposomal Form: Effect of Different Injection Routes
To find out whether the fact, that liposomal DB67 admin-
istered intravenously has a higher therapeutic effect than
either DB67 or liposomal DB67 when administered intra-
peritoneally, could be correlated with a higher tissue accu-
mulation, we studied DB67 accumulation in spleen and liver
of Balb/C mice after its injection in free or liposomal form,
using both administration routes. The results are expressed
as percentages of the injected dose ±SD per gram of tissue
and were determined in mice 0.5 and 2 hours after injection
of a dose of 7 mg/kg. The results of this set of experiments
are shown in Table 6. The results obtained for spleen and
liver show that higher percentages of the injected dose of
DB67 are found 0.5 hour after injection than 2 hours after in
any of its forms. At 2 hours, in the spleen, less than 1% of the
injected dose is found for DB67 injected in any of its forms.
On the other hand, nearly 5% of the injected dose was found
in the liver at 2 hours after the injection of DB67 in any of its
forms. When DB67 in free or liposomal form was injected
intraperitoneally, similar percentages of the injected dose
were found in the spleen and liver at any time point. On the
contrary, when liposomal DB67 was injected intravenously,
a higher percentage of the injected dose was found in the
spleen and liver compared to itself or to DB67 in free form
injected intraperitoneally. Therefore, the fraction of the
injected dose of DB67 found in the spleen and liver was
related to the injection route.
Cytotoxicity of DB67 and Liposomal DB67 as a Function
of Time
The cytotoxicity of DB67 and liposomal DB67 to murine
CT-26 colon carcinoma cell line was compared as a function
of time. As shown in Table 7, when the incubation time was
continuous for 48 hours, IC50 values of DB67 and liposomal
DB67 were 0.024 ± 0.004 and 0.019 ± 0.002 mg/ml, respec-
tively. When the incubation time was limited to 2 hours, IC50
values of DB67 and liposomal DB67 were 1.40 ± 0.13 and
1.40 ± 0.15 mg/ml, respectively. No statistically significantly
differences were found between the IC50 values of these two
treatments and for both incubation times studied. As
expected, the reduction of the incubation time of the drug
with the cells is related with the increase in the IC50 values.
The IC50 values of free and liposomal DB67, as a function of
time, are very similar and produce the same cytotoxic effect
when cells are treated with free or liposomal DB67 even at
2 hours of incubation time. The comparison of IC50 values
between free and liposomal DB67, as a function of time,
suggests that the cells have the same availability for DB67
when treated with DB67 either in free or liposomal form.
Table 5. Effect of Liposomal DB67 and Irinotecan on Survival in a Murine CT-26 Colon Carcinoma.
Experiment Treatment Dose (mg/kg) Mean Survival Time* (day ± SD) ILS (%)y Long-Term Survivorsz/Total Mice
1 Control – 21.0 ± 1.0 – 0/7
Lipo-DB67 7  5 30.5 ± 2.7§,b,# 45 1/7
Irinotecan 55  5 26.7 ± 3.6** 27 0/7
2 Control – 19.0 ± 0.0 – 0/6
Lipo-DB67 7  5 30.8 ± 3.9§,b,# 62 1/6
Irinotecan 55  5 26.5 ± 4.1** 39 0/6
Balb/C mice were injected in the spleen with 5 104 viable CT–26 cells on day 0. Seven days later, mice were splenectomized. On day 14 after cell injection,
groups of mice were treated on a schedule of daily i.v. injection for 5 days (qdx5/1), by 21-day cycles when necessary, with doses as follows.
*Days after cell injection.
yWas obtained using the formula: (T  100/C)  100, where T is median survival of treated mice (in days) over C control.
zFor more than 90 days.
§Mean survival time results include only dead mice, not survivors.
bP < .01 as compared to control (no treatment) using the log-rank test.
#P < .05 as compared to irinotecan using the log-rank test.
**P < .05 as compared to control (no treatment) using the log-rank test.
Table 6. Tissue Accumulation of DB67 After Its Injection in Free or
Liposomal Form.
Treatment Time
(hours)
Percent Injected Dose Per Gram of Tissue
Spleen Liver
i.p. i.v. i.p. i.v.
DB67 0.5 1.95 ± 0.43 – 11.02 ± 1.05 –
2 0.69 ± 0.10 – 4.80 ± 1.27 –
Lipo-DB67 0.5 2.21 ± 0.33 3.50 ± 0.45 12.01 ± 1.27 15.98 ± 1.00
2 0.23 ± 0.03 0.23 ± 0.05 4.80 ± 0.42 4.60 ± 0.45
In both cases, DB67 was injected intraperitoneally or intravenously as a
single bolus of 7 mg/kg. Balb/c mice were sacrificed at indicated time points
after injection. Tissue samples were collected and analysed for drug content
(see Materials and Methods section). The values are expressed as
percentage of the injected dose ±SD per gram of tissue of five mice per
group.
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Discussion
In this study, we have shown that liposomes allow DB67 to
be administered intravenously and, using this route of injec-
tion, liposomal DB67 is more effective than DB67 in free form
or even itself administered intraperitoneally in the treatment
of liver metastases of a colorectal carcinoma after resection
of the primary tumor, due to a higher liver accumulation.
Using the same model, liposomal DB67 is also more effec-
tive than irinotecan.
DB67 belongs to the family of topo I inhibitors, which are
termed S-phase–specific because when DNA replicates, it is
more susceptible to single-strand breaks in their presence
[7,33]. Consequently, a continuous exposure to a topo I
inhibitor is lethal to a larger proportion of tumor cells. Pre-
clinical and clinical data suggest that frequent administration
of lower doses of irinotecan, ensuring a prolonged exposure
time, may be more effective than higher doses given at
longer intervals [32,34,35]. Under this rationale, we used
the qdx5/1 schedule in all experiments. Intraperitoneal ad-
ministration of DB67, as well as i.p. and i.v. administration of
liposomal DB67, in all cases at a dose of 7 mg/kg per day
caused less than 10% of BW loss in mice and were well
tolerated, and therefore this dose was chosen in the following
therapy experiments.
Due to its high lipophilicity, DB67 cannot be dissolved in
aqueous media, and therefore is not suitable for i.v. admin-
istration. The incorporation of DB67 in liposomes overcomes
this difficulty, allowing liposomal DB67 to be resuspended
in aqueous media and be used for frequent i.v. administra-
tion. Otherwise, DB67 would have to be resuspended in
organic compounds that are toxic when administered intra-
venously. The results demonstrate that DB67 injected intra-
peritoneally and liposomal DB67 injected intraperitoneally
and intravenously were equally toxic in the daily 5 sched-
ule. The routes of administration used, i.p. and i.v., do not
play an important role in the toxicity of DB67 in any of its
forms. However, in therapy experiments with mice bearing
ectotopic or orthotopic malignant glioma tumors, animals
were treated using the same schedule used here, but at a
dose of 30 mg/kg per day with DB67 in free form and using
the s.c. route [26]. Our toxicity results demonstrate that,
using this schedule, the therapeutic dose of DB67 or liposo-
mal DB67 administered intraperitoneally or intravenously is
7 mg/kg per day. This difference in the dose used is related
to the route of administration: s.c. injection versus i.p. or
i.v. injection [36].
In the therapy experiments, we used two approaches:
first, when the primary tumor is present (in this case, the
treatment started 10 days after cell inoculation); and, sec-
ond, after the primary tumor was surgically resected. This
second approach was done to mimic the clinical situation
when the primary tumor is surgically removed and the effect
of the therapy against liver metastases is studied. In this
latter case, the treatment started 7 days after the splenecto-
my. In both cases, the treatment started when the disease
was at an advanced stage [37].
In the first approach, when the treatment was given
intraperitoneally, DB67 and liposomal DB67 caused a reduc-
tion of less than 27% in the splenic primary tumor volume
and 44% in the liver weight, both compared with the control.
Tissue accumulation experiments showed that after injec-
tion of DB67 or liposomal DB67, there is a similar fraction of
the injected dose of DB67 in the spleen for the time period
studied. In the liver, a higher fraction of the injected dose was
found, but it was again similar for both treatments. That
explains the similar antitumor effect found between DB67
and liposomal DB67 in reducing the splenic primary tumor
and liver metastasis. When the treatment was given intrave-
nously, liposomal DB67 caused a reduction of 55% in the
splenic primary tumor volume and of 40% in the liver weight,
both compared with the control. The primary tumor volume
reduction was then higher than that obtained when liposo-
mal DB67 was given intraperitoneally. In this case, for spleen
and liver, the fraction of the injected dose was 58% higher at
0.5 hour compared with the fraction found when the treat-
ment was given intraperitoneally. The schedule used, daily
for 5 days, contributes to increase this difference at the
end of the therapeutic period. When liposomes are injected
intraperitoneally or intravenously, a preferential uptake by
organs of the mononuclear phagocytic system (MPS), prin-
cipally liver and spleen, has been described [36]. In addition,
the fast and easy accessibility to these organs once the
liposomes are in the bloodstream after their i.v. injection can
explain the higher accumulation found after i.v. injection. In
contrast, irinotecan administered intraperitoneally caused a
reduction of 82% in the splenic primary tumor volume, and
of 68% in the liver weight, both compared with the control.
Similar results were found when it was administered intra-
venously. The route of administration does not therefore
play an important role in the efficacy of irinotecan because
it was equally effective given i.p. or i.v. administrations in
the daily 5 days schedule as previously demonstrated
[31,32]. The high efficacy of irinotecan reducing spleen
primary tumor volume is surprising because we have not
found anything in the literature data describing this effect. In
addition, we have not found either data regarding levels of
accumulation of irinotecan or SN-38 in spleen and liver that
could explain this effect nor any validated method for that
quantification.
The higher fraction of the injected dose that reaches the
liver after liposomal DB67 injected intravenously does not
cause a reduction in the liver weight, compared with the
Table 7. Cytotoxicity of DB67 and Liposomal DB67 as a Function of Time.
Topo I Inhibitor IC50 (mg/ml)
y
2 hours 48 hours
DB 67 1.40 ± 0.13 0.024 ± 0.004
Lipo-DB67 1.40 ± 0.15 0.019 ± 0.002
CT-26 colon carcinoma cells at a density of 2.5 103 viable cells were plated
in 96-well microtiter plates. On the second day, various concentrations of
DB67 and liposomal DB67 were added for 2 or 48 hours. Cytotoxicity was
determined using the MTT assay.*
*The data are represented as mean ± SD of three independent experiments
done in triplicate.
y IC50 is the concentration of drug that caused a 50% inhibition of the control
growth.
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lower fraction found after i.p. injection. This higher fraction of
DB67 may not be enough to suppress the growth of the
tumor cells that are continuously leaving the primary tumor
and locating in the liver. Metastatic cells leave the primary
tumor to colonize other organs [38]. In particular, CT-26 in
the splenic primary tumor metastasize to the liver [39].
Irinotecan caused a more effective reduction in splenic
primary tumor volume (82%), which probably reduced the
number of tumor cells available to leave the spleen and able
to metastasize to the liver.
In the second approach, the primary tumor is removed.
When the treatment was given intraperitoneally, DB67 and
liposomal DB67 caused nearly a 50% reduction in the liver
weight compared with the control. The fraction of the injected
dose that reaches the liver is similar for both treatments at
the time points studied. The data give support to the previ-
ous therapy results. When the treatment was given intrave-
nously, liposomal DB67 caused the more effective reduction
in the liver weight (65%) compared with the control. The
fraction of the injected dose found at 0.5 hour in the liver
after the i.v. injection of liposomal DB67 is 45% higher than
that found when it was injected intraperitoneally.
Surprisingly, the treatment with irinotecan given intraper-
itoneally or intravenously caused a reduction of less than
33% in the liver weight. Such reduction is half of that found
for irinotecan in the presence of the primary tumor and may
be an indicator of irinotecan liver accumulation. Under this
latter approach, the number of cells continuously leaving the
splenic primary tumor and reaching the liver is abrogated on
day 7 after cell inoculation. The subsequent growth of liver
metastases will be from those already present at that time
in the liver tissue. In the presence of the primary tumor,
irinotecan reduced by 82% the splenic primary tumor vol-
ume and probably at the same time caused an important
reduction in the number of tumor cells available to leave the
primary tumor and able to colonize the liver. That may result
in a reduction in liver colonies formation and finally in the
liver weight.
Continuing in this second approach, survival experiments
confirmed the results of previous experiments. Liposomal
DB67 injected intravenously with a multiple dosing schedule
was more effective, increasing by about 2.7 times the medi-
an lifespan of treated mice, as compared with irinotecan. Of
greater importance is the presence of one long-term survivor
for more than 90 days in each of two experiments after
treatment with liposomal DB67. The liposomal carrier system
of DB67 made i.v. injection of DB67 possible, thus increas-
ing the survival of mice treated with it.
When CT-26 tumor was induced subcutaneously, the
treatment with DB67, liposomal DB67, and irinotecan using
the i.p. or i.v. route of administration caused only a short
delay in tumor growth, compared with the control (results not
shown). The cause of this result could be due to the short
circulation time once in the bloodstream described for DB67,
liposomal DB67, and irinotecan, which enabled only little
amounts of the drug to enter the growing s.c. tumor [14,40].
The close relationship between s.c. tumor drug accumulation
and blood circulation time has been previously demonstrated
[41,42]. Encapsulation of antitumor drugs in liposomes has
been used to increase their antitumor activity and to de-
crease undesired side effects, compared to those of free
drug. Irinotecan has been encapsulated in conventional rigid
[43] and peguilated liposomes [44], thus acting as a slow-
release drug delivery system to achieve an increased circu-
lation time of the drug itself and SN-38 in plasma and a
reduction in the uptake by the MPS in the liver and spleen.
That increased circulation time in plasma leads to a passive
targeting to the subcutaneously induced tumor, which brings
an increase in irinotecan and SN-38 accumulation in tumor.
This result is a reduction in tumor weight [44] and an
enhanced antitumor activity [43]. However, in our tumor
model, our objective was the treatment of the metastatic
cells growing specifically in the liver. In that case, DB67 and
liposomal DB67 caused a significant reduction in the liver
weight, compared to irinotecan, when the primary tumor
was surgically removed. The increased activity of liposomal
DB67 is dependent on enhanced tumor accumulation in the
liver, and thusDB67 is a serious candidate for the treatment of
liver metastases as an adjuvant to chemotherapy. Also, it is
important to note that liposomal DB67 is not a slow-release
drug system, as cytotoxicity assays demonstrate. DB67 is
lipid-bound to the liposome bilayers [24]. This type of inter-
actionmay cause, firstly, the same toxicity found in vitro, and,
secondly, a similar tissue accumulation in liver and spleen
than after its administration using the i.p. route of injection.
Two reasons encourage the continuation of experimen-
tation in humans with liposomal DB67: first, DB67 exhibits
higher human blood stability, measured as a percentage of
lactone form (30%), as compared with SN-38 (20%) or
irinotecan (21%) [23]; and, second, the observation that mice
convert irinotecan to SN-38 to a much greater extent than
humans [31].
As a conclusion, the incorporation of DB67 in liposomes
made possible the injection of the lipophilic drug DB67
intravenously, thereby increasing liposomal DB67 therapeu-
tic effectiveness, as compared with itself and its free form
administered intraperitoneally against liver metastases of a
murine colon carcinoma after resection of the primary tumor.
This enhanced efficacy is due to a higher liver drug accu-
mulation after using the i.v. route of injection. Using this
same model, it is also more effective than irinotecan.
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